Abstract
Chronic obstructive pulmonary disease (COPD) was the fourth leading cause of death worldwide in 2015. Current treatments for patients ease discomfort and help decrease disease progression; however, none improve lung function or change mortality. COPD is heterogeneous in its molecular and clinical presentation, making it difficult to understand disease aetiology and define robust therapeutic strategies. Given the complexity of the disease we propose a precision medicine approach to understanding and better treating COPD. It is possible that multiOMICs can be used as a tool to integrate data from multiple fields. Moreover, analysis of electronic medical records could aid in the treatment of patients and in the predictions of outcomes. The Precision Medicine Initiative created in 2015 has made precision medicine approaches to treat disease a reality; one of these diseases being COPD.
Abstract
MultiOMICs integration of clinical and molecular markers is needed to predict patient outcomes in COPD http://ow.ly/cnhj30kBxfd
Footnotes
Number 8 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
Provenance: Commissioned article, peer reviewed.
Previous articles in this series: No. 1: Chung KF. Personalised medicine in asthma: time for action. Eur Respir Rev 2017; 26: 170064. No. 2: Bonsignore MR, Suarez Giron MC, Marrone O, et al. Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment. Eur Respir Rev 2017; 26: 170069. No. 3: Mascaux C, Tomasini P, Greillier L, et al. Personalised medicine for nonsmall cell lung cancer. Eur Respir Rev 2017; 26: 170066. No. 4: Noell G, Faner R, Augusti A. From systems biology to P4 medicine: applications in respiratory medicine. Eur Respir Rev 2018; 27: 170110. No. 5: Wouters EFM, Wouters BBREF, Augustin IML, et al. Personalised pulmonary rehabilitation in COPD. Eur Respir Rev 2018; 27: 170125. No. 6: Kokosi MA, Margaritopoulos GA, Wells AU. Personalised medicine in interstitial lung diseases. Eur Respir Rev 2018; 27: 170117. No. 7: Savale L, Guignabert C, Weatherald J, et al. Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. Eur Respir Rev 2018; 27: 180004.
Author contributions: All authors contributed to the conception and design of the manuscript.
Conflict of interest: F.J. Martinez reports personal fees and non-financial support from the American College of Chest Physicians (personal fee honoraria and non-personal travel support for COPD CME programmes in India), personal fees and non-financial support from AstraZeneca (personal fees and non-personal travel support for COPD advisory boards, a study steering committee and an ALAT presentation), personal fees and non-financial support from Boehringer Ingelheim (personal fees and non-personal travel support for a COPD advisory board, and personal fees for an ATS presentation), non-financial support from ProterrixBio (support for an NIH study, but no direct financial compensation for a COPD scientific advisory board), personal fees and non-financial support from Continuing Education (personal fee honorarium and non-personal travel support for a cough CME programme), personal fees from Columbia University, Haymarket Communications, Integritas, Methodist Hospital Brooklyn, New York University, UpToDate, WebMD/MedScape and Western Connecticut Health Network (personal fee honoraria for COPD CME programmes), personal fees and non-financial support from ConCert, Pearl Pharmaceuticals, Roche, Sunovion and Theravance (personal fee honoraria and non-personal travel support for COPD advisory boards), personal fees and non-financial support from Genentech (personal fee and non-personal travel support for a COPD advisory board and non-financial support for an asthma data safety monitoring board), personal fees and non-financial support from GlaxoSmithKline (personal fee honoraria and non-personal travel support for COPD advisory boards, non-personal travel support for a study steering committee and an ERS presentation, and academic co-authorship for a data safety monitoring board), personal fees and non-financial support from Inova Fairfax Health System, Miller Communications, the National Association for Continuing Education, PeerView Communications, Prime Communications, the Puerto Rican Respiratory Society and Chiesi (personal fee honoraria and non-personal travel support for COPD CME programmes), personal fees from Inthought Research (personal fee honoraria for a COPD/asthma teleconference), personal fees from MD Magazine (personal fee honorarium and non-personal travel support for a COPD CME programme), personal fees and non-financial support from Novartis (personal fees honoraria and non-personal travel support for a COPD advisory board and international meeting COPD disease presentations), personal fees from Unity (personal fee honoraria for a COPD teleconference), personal fees from the American Thoracic Society (personal fee honoraria for being deputy editor of the AJRCCM), and a grant from the National Institutes of Health (COPD UO1/RO1).
Support statement: Supported by R01HL124099 (to V.K. Sidhaye) and SPIROMICS, which was supported by contracts from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune, Bayer, Bellerophon Therapeutics, Boehringer-Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici SpA., Forest Research Institute, Inc., GlaxoSmithKline, Grifols Therapeutics, Inc., Ikaria, Inc., Nycomed GmbH, Takeda Pharmaceutical Company, Novartis Pharmaceuticals Corporation, ProterixBio, Regeneron Pharmaceuticals, Inc., Sanofi and Sunovion. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received March 15, 2018.
- Accepted June 18, 2018.
- Copyright ©ERS 2018.
ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.